November 21, 2016 - By Nellie Frank · 0 Comments
Sophiris Bio Inc (NASDAQ:SPHS) institutional sentiment increased to 2.33 in Q2 2016. Its up 1.56, from 0.77 in 2016Q1. The ratio improved, as 10 hedge funds opened new or increased holdings, while 13 decreased and sold their stakes in Sophiris Bio Inc. The hedge funds in our partner’s database now hold: 1.50 million shares, down from 2.18 million shares in 2016Q1. Also, the number of hedge funds holding Sophiris Bio Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 8 Reduced: 5 Increased: 5 New Position: 5.
Sophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada biopharmaceutical firm focused on the research, development and commercialization of products for the treatment of urological diseases. The company has a market cap of $84.90 million. The Firm has activities based in San Diego developing a treatment for benign prostatic hyperplasia or enlarged prostate). It currently has negative earnings. The Firm has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan.
About 36,210 shares traded hands. Sophiris Bio Inc (NASDAQ:SPHS) has risen 113.64% since April 19, 2016 and is uptrending. It has outperformed by 109.78% the S&P500.
According to Zacks Investment Research, “Sophiris Bio Inc. operates as a biopharmaceutical company. The Company is developing a treatment for benign prostatic hyperplasia (BPH or enlarged prostate). It has operations based in San Diego. Sophiris Bio Inc. is based in Canada.”
Palo Alto Investors Llc holds 0.08% of its portfolio in Sophiris Bio Inc for 494,000 shares. Rock Springs Capital Management Lp owns 490,000 shares or 0.08% of their US portfolio. Moreover, Airain Ltd has 0% invested in the company for 32,017 shares. The North Carolina-based Bank Of America Corp De has invested 0% in the stock. Bank Of Montreal Can, a Ontario – Canada-based fund reported 1,632 shares.#img1#
Ratings analysis reveals 100% of Sophiris Bio’s analysts are positive. Out of 3 Wall Street analysts rating Sophiris Bio, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $7 while the high is $8. The stock’s average target of $7.67 is 174.91% above today’s ($2.79) share price. SPHS was included in 3 notes of analysts from August 30, 2016. The firm has “Overweight” rating given on Tuesday, August 30 by Piper Jaffray. The rating was initiated by Roth Capital on Thursday, September 15 with “Buy”. TH Capital initiated it with “Buy” rating and $8 target price in Thursday, September 15 report.
Sophiris Bio Inc., incorporated on May 1, 2003, is a clinical-stage biopharmaceutical company. The Firm is focused on developing products for the treatment of urological diseases. The Firm is developing topsalysin (PRX302) as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH) commonly referred to as an enlarged prostate and as a treatment for localized low to intermediate risk prostate cancer.
More important recent Sophiris Bio Inc (NASDAQ:SPHS) news were published by: Prnewswire.com which released: “Sophiris Bio Reports Third Quarter 2016 Financial Results and Key Business …” on November 09, 2016, also Prnewswire.com published article titled: “Sophiris Bio Prices Public Offering of Common Shares and Warrants”, Prnewswire.com published: “Sophiris Bio To Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as …” on May 05, 2016. More interesting news about Sophiris Bio Inc (NASDAQ:SPHS) was released by: Prnewswire.com and their article: “Sophiris Bio Inc. to Raise Approximately $5 Million Through At-the-Market Offering” with publication date: May 06, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Nellie Frank